Type of information: Collaboration agreement
Compound: cognitive solution to provide insights on the expected outcomes of breast cancer treatment options
Company: Novartis (Switzerland) IBM Watson Health (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: artificial intelligence. Watson is a commercially available cognitive computing capability. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions.
Disease: breast cancer
- • On June 5, 2017, Novartis announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes. The two companies will collaborate to explore development of a cognitive solution that uses real-world data and advanced analytical techniques with the aim to provide better insights on the expected outcomes of breast cancer treatment options.
- This collaboration will join Novartis expertise in breast cancer with IBM Watson Health skill in data analytics and machine learning to determine which combinations and sequences may lead to the best patient outcomes. The initiative primarily will use real-world patient data.
- Novartis has currently four marketed products in breast cancer: Kisqali®* (ribociclib), Afinitor® (everolimus), Tykerb®/Tyverb® (lapatinib) and Femara® (letrozole). Novartis also has the largest number of breast cancer compounds in development, including BYL719 (alpelisib), an alpha-specific PI3K inhibitor; LSZ102, an oral SERD; LJM716, a fully human, anti-HER3 IgG1 antibody; and MCS110, a colony-stimulating factor 1 (CSF1) inhibitor.